TAG:
PAMA
Labcorp and Quest Execs Support RESULTS Act Progress
Chief executives at both Labcorp and Quest Diagnostics reported year-over-year revenue growth in the first quarter during recent earnings calls, especially in specialty and consumer testing. They also indicated the companies are watching the progress of the RESULTS Act in Congress in hopes that it wi…
Behind the Cat-and-Mouse Game of Lab Reimbursement
Financial relationships between clinical laboratories and commercial payers have evolved into a high-stakes, technological tug-of-war. For nearly a decade, the clinical laboratory industry has wrestled with the provisions of the Protecting Acce…
May 26, 2026, Intelligence: Late-Breaking Lab News
UnitedHealthcare is expanding rural healthcare initiatives that could provide operational relief for clinical laboratories in underserved communities. The effort focuses on improving cash flow, reducing administrative burdens, and strengthening financial stability for rural hospitals an…
Risk of Complacency May Be the Biggest Threat
Prevailing sentiment at the recent Executiv…
Expect RESULTS Act Vote by End of the Year
CEO SUMMARY: Evidence at the 2026 Executive War College suggests a coming push in clinical lab advocacy, focusing on the RESULTS Act to establish a permanent, database-driven reimbursement model. Simultaneously, federal regulators have floated the idea of heightened scruti…
In Earnings Calls, Execs at Quest and Labcorp Push for RESULTS Act
Chief executives at Labcorp and Quest Diagnostics made it clear during recent investor calls that they want Congress to pass the RESULTS Act. The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act is seen b…
Clinical Labs Must Prep for Heightened Audits
CEO SUMMARY: A new report from the Office of Inspector General sheds interesting light on just how much genetic testing has increased among Medicare Part B beneficiaries. With billions of dollars in reimbursement at stake for clinical laboratories, expect federal officials…
Office of Inspector General Briefs
Congress Wants Review of Test Fraud As part of a spending bill approved by Congress recently, there is a small provision that hints at future review of clinical laboratory tests by the US Department of Health and Human Services’ Office of Inspector General (OIG)….
Permanent PAMA Reform Must Happen in 2026
Previously, it would have been hard to imagine …
PAMA Cuts Averted Until ‘27; Labs Plan Next Move
CEO SUMMARY: Clinical laboratories have again avoided a potential financial disaster, at least for now, after Congress shifted PAMA cuts to test reimbursement rates until January 2027. However, the victory is temporary absent permanent PAMA reform. To that end, laboratory …
CURRENT ISSUE
Volume XXXIII, No. 9 – July, 2026
Newsmaker Interview with Revvity’s Yves Dubaquie > How Specialty Diagnostic Tests Connect with Lab Customers: In this exclusive Q&A, Revvity’s Yves Dubaquie provides details about the in vitro diagnostics company’s priorities, including developing specialty tests and reviewing its business in China. Dubaquie also explains why clinical laboratories may need to consider hiring more technology-savvy workers in the future as the complexity of instruments grows.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.